Safe use of hydroxycarbamide in sickle cell disease patients hospitalized for painful vaso‐occlusive episodes during the randomized, open‐label HELPS study.

Four and three patients in each group (respectively) were on continuous HC therapy upon inclusion, and one patient in the non-intervention arm continued taking HC (20 mg/kg/day) throughout the study (the other patients in this group did not take their medication to the ER). Safe use of hydroxycarbamide in sickle cell disease patients hospitalized for painful vaso-occlusive episodes during the randomized, open-label HELPS study. [Extracted from the article]